0000000000205214

AUTHOR

Hanno Riess

showing 4 related works from this author

CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks—A prospective r…

2015

4007 Background: Adjuvant chemotherapy with gemcitabine (Gem) for 6 months significantly improves survival of pancreatic cancer patients. CONKO-005 was designed to evaluate an additional effect of ...

Oncology0303 health sciencesCancer Researchmedicine.medical_specialtyendocrine system diseasesAdjuvant chemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisPancreatic cancerInternal medicinemedicineAdjuvant therapyErlotinibbusiness030304 developmental biologymedicine.drugJournal of Clinical Oncology
researchProduct

CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Mult…

2017

Purpose Gemcitabine is standard of care in the adjuvant treatment of resectable pancreatic ductal adenocarcinoma (PDAC). The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in combination with gemcitabine has shown efficacy in the treatment of advanced PDAC and was considered to improve survival in patients with primarily resectable PDAC after R0 resection. Patients and Methods In an open-label, multicenter trial, patients were randomly assigned to one of two study arms: gemcitabine 1,000 mg/m2 days 1, 8, 15, every 4 weeks plus erlotinib 100 mg once per day (GemErlo) or gemcitabine (Gem) alone for six cycles. The primary end point of the study was to improve disease-fre…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineMulticenter trialPancreatic cancermedicineClinical endpointChemotherapybusiness.industrymedicine.diseaseGemcitabine3. Good healthClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisErlotinibbusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial o…

2015

4082 Background: Biliary tract cancer encompasses a group of genetically heterogeneous tumors. Panitumumab is a human EGFR inhibitor and has shown anti-tumor activity in RAS WT colorectal cancer. M...

OncologyCancer Researchmedicine.medical_specialtyBiliary tract cancerbusiness.industryColorectal cancerGemcitabine/cisplatinmedicine.disease_causemedicine.diseaseOncologyInternal medicineMedicinePanitumumabKRASbusinessmedicine.drugEGFR inhibitorsJournal of Clinical Oncology
researchProduct

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

2012

ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G…

medicine.medical_specialtyGastrointestinal tumorsPerformance statusbusiness.industryHematologySevere hypoxiaNeutropeniamedicine.diseaseRashGastroenterologyDiscontinuationNon colorectalOncologyInternal medicineToxicitymedicinemedicine.symptombusinessAnnals of Oncology
researchProduct